The Combination of Epirubicin plus Docetaxel as Neoadjuvant Chemotherapy in Locally-advanced Breast Cancer

Background: The purpose of this study was to evaluate the activity and toxicity of epirubicin plus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer. Patients and Methods: In this single-center, phase II trial, twenty-one patients with locally advanced breast cancer (T>3 cm...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-01, Vol.26 (1B), p.581-584
Main Authors: HIRANO, Akira, SHIMIZU, Tadao, OGAWA, Kenji, IMAMURA, Hiroshi, WATANABE, Osamu, KINOSHITA, Jun, OKABE, Toshihiro, KIMURA, Kiyomi, KAMIMURA, Mari, DOMOTO, Kaoru, AIBA, Motohiko
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Chemotherapy, Adjuvant
Epirubicin - administration & dosage
Epirubicin - adverse effects
Female
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Middle Aged
Neoadjuvant Therapy
Taxoids - administration & dosage
Taxoids - adverse effects
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The purpose of this study was to evaluate the activity and toxicity of epirubicin plus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer. Patients and Methods: In this single-center, phase II trial, twenty-one patients with locally advanced breast cancer (T>3 cm or N>1) received epirubicin (70 mg/m 2 ) and docetaxel (60 mg/m 2 ) on Day 1 of each cycle for up to 6 cycles. Results: Clinically complete responses (CR) were observed in 5 patients and partial responses were observed in 14 patients. The clinical response rate was 90.5% (95% confidence interval, 78.0-99.9). Eleven patients (52.4%) underwent breast conserving surgery. Pathological response evaluation revealed 2 CR (9.5%). Grade 4 neutropenia was recorded in 81.0% of the patients and febrile neutropenia occurred in 1 patient. Conclusion: The combination of epirubicin plus docetaxel was an active and well-tolerated treatment for locally-advanced breast cancer.
ISSN:0250-7005
1791-7530